A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Project: Research

Project Details

StatusActive
Effective start/end date6/12/225/12/27